India’s second-largest pharmaceutical company, Dr Reddy’s Laboratories Ltd, said it had agreed to buy eight generic drugs from Teva Pharmaceutical Industries and Allergan Plc for $350 million in cash in an attempt to bolster its U.S. business.
The drugs Dr Reddy’s has agreed to buy are being divested by Israel-based Teva, in order to win U.S. antitrust clearance for its $40.5 billion acquisition of Allergan’s generic drugs portfolio. This sale to Dr Reddy’s puts Teva one step closer to closing the Allergan deal.
The deal consists of some generic drugs awaiting U.S. approval, as well as some that are already on the market. The branded versions of drugs under the deal had U.S. sales of about $3.5 billion in the year leading to April 2016, the company reported citing healthcare research firm IMS Health.
Full Content: NBC Daily
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Urged to Enforce Rarely Used Antitrust Law Against Retail Giants
Mar 28, 2024 by
CPI
UK’s Fingleton Bolsters Team with New Additions
Mar 28, 2024 by
CPI
Britain’s Competition Regulator Clears Aviva’s Acquisition of AIG Life UK
Mar 28, 2024 by
CPI
White House Implements New AI Safeguards to Protect Rights and Safety
Mar 28, 2024 by
CPI
Denver Court Sets August Date for Kroger-Albertsons Merger Showdown
Mar 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Real Estate & Antitrust
Mar 27, 2024 by
CPI
Systematic National Evidence of Steering by Real Estate Agents
Mar 27, 2024 by
CPI
Compliance Now! Actionable Antitrust Advice for the Residential Real Estate Industry
Mar 27, 2024 by
CPI
Real Estate Commissions: Some Insights from the Economics of Multi-Sided Platforms
Mar 27, 2024 by
CPI
New Ideas for Promoting Real Estate Brokerage Price Competition
Mar 27, 2024 by
CPI